Zubsolv sales of SEK417m were up 83% on FY14, against overall 7.8% market growth. As expected, its 6.4% market share at end FY15 was eroded in January due to the loss of favourable reimbursement status at CVS Caremark. Nevertheless, a 5% price rise, effective February, coupled with a targeted sales effort and stronger marketing message, should help drive sales, particularly as Zubsolv’s reimbursement position improves. With changes in federal legislation on the cusp of significantly inc
17 Feb 2016
Short-term pain; on the cusp of longer-term gains
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Short-term pain; on the cusp of longer-term gains
Zubsolv sales of SEK417m were up 83% on FY14, against overall 7.8% market growth. As expected, its 6.4% market share at end FY15 was eroded in January due to the loss of favourable reimbursement status at CVS Caremark. Nevertheless, a 5% price rise, effective February, coupled with a targeted sales effort and stronger marketing message, should help drive sales, particularly as Zubsolv’s reimbursement position improves. With changes in federal legislation on the cusp of significantly inc